<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3c.org/TR/1999/REC-html401-19991224/loose.dtd">
<HTML lang=en xml:lang="en" xmlns="http://www.w3.org/1999/xhtml"><HEAD><TITLE>SARS-CoV-2: The Battle against COVID-19 has just Begun</TITLE>
<META content="text/html; charset=utf-8" http-equiv=Content-Type>
<META name=GENERATOR content="MSHTML 8.00.6001.23562"></HEAD>
<BODY bgColor=#ffffff>
<DIV><FONT size=2 face=Arial></FONT><BR></DIV>
<STYLE id=bmeresponsecss type=text/css>
@media Unknown
{
BODY {
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px
}
TABLE[class=container-table] {
WIDTH: 95% !important
}
.bmeheadertext {
WIDTH: 95% !important
}
.container-table {
WIDTH: 95% !important
}
.header {
FONT-SIZE: 24px !important
}
.contenttitle {
LINE-HEIGHT: 140% !important; FONT-SIZE: 20px !important
}
.contenttext {
LINE-HEIGHT: 140% !important; FONT-SIZE: 16px !important
}
.single-col {
WIDTH: 100% !important; DISPLAY: block !important; FLOAT: left; CLEAR: both
}
IMG.mobile-img-large {
WIDTH: 100% !important; DISPLAY: block; HEIGHT: auto !important
}
IMG.bmeRSSImage {
MAX-WIDTH: 300px; HEIGHT: auto !important
}
TD[class='preheader-table'] {
PADDING-BOTTOM: 10px !important; PADDING-LEFT: 0px !important; PADDING-RIGHT: 0px !important; PADDING-TOP: 10px !important
}
DIV[class='bmeheadertext'] {
LINE-HEIGHT: 140% !important; FONT-SIZE: 12px !important
}
TD[class='bmefootertext'] {
LINE-HEIGHT: 140% !important; FONT-SIZE: 12px !important; PADDING-TOP: 10px
}
DIV[class='bmefootertext'] {
LINE-HEIGHT: 140% !important; FONT-SIZE: 12px !important; PADDING-TOP: 10px
}
DIV[class='bmefooter'] TD[width='79%'] {
WIDTH: 100%; DISPLAY: block !important
}
DIV[class='bmefooter'] TD[width='21%'] {
WIDTH: 100%; DISPLAY: block !important
}
.mobile-footer {
LINE-HEIGHT: 18px !important; FONT-SIZE: 13px !important
}
.mobile-footer A {
LINE-HEIGHT: 18px !important; FONT-SIZE: 13px !important
}
.mobile-footer {
TEXT-ALIGN: center !important
}
DIV.bmefooter {
DISPLAY: block !important
}
DIV.bmeheader {
DISPLAY: block !important
}
TABLE[class='share-tbl'] {
PADDING-BOTTOM: 15px; WIDTH: 100% !important
}
TABLE[class='share-tbl'] TD {
TEXT-ALIGN: center !important; WIDTH: 100% !important; DISPLAY: block !important
}
IMG.bmeRSSImage {
MAX-WIDTH: 500px !important; HEIGHT: auto !important
}
}
</STYLE>
<TABLE
style="BORDER-RIGHT-WIDTH: 0px; MARGIN: 0px; BORDER-SPACING: 0; BORDER-COLLAPSE: collapse; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px"
width="100%" bgColor=#f6f4f5 align=center>
<TBODY>
<TR>
<TD
style="PADDING-BOTTOM: 13px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 13px"
vAlign=top align=middle>
<TABLE
style="PADDING-BOTTOM: 0px; BORDER-RIGHT-WIDTH: 0px; MARGIN: 0px; PADDING-LEFT: 0px; BORDER-SPACING: 0; PADDING-RIGHT: 0px; BORDER-COLLAPSE: collapse; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; PADDING-TOP: 0px"
width=700 bgColor=#ffffff align=center><!-- Header -->
<TBODY>
<TR>
<TD
style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 15px"
height=80 vAlign=top align=middle><A
href="http://medchemexpress.benchurl.com/c/l?u=A2354DE&e=101B0B6&c=98B9B&t=0&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&seq=1"
target=_blank><IMG
style="BORDER-RIGHT-WIDTH: 0px; DISPLAY: block; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px"
alt=""
src="https://file.medchemexpress.com/images/sars-cov-2-logo-bar.png"
width=676 height=55> </A></TD></TR><!-- Banner -->
<TR>
<TD
style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=165 vAlign=top align=middle><IMG
style="BORDER-RIGHT-WIDTH: 0px; DISPLAY: block; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px"
alt=""
src="https://file.medchemexpress.com/images/sars-cov-2-banner.jpg"
width=676 height=146> </TD></TR><!-- Content -->
<TR>
<TD
style="PADDING-BOTTOM: 0px; PADDING-LEFT: 12px; PADDING-RIGHT: 12px; PADDING-TOP: 0px"
height=60 vAlign=top>
<TABLE
style="PADDING-BOTTOM: 0px; BORDER-RIGHT-WIDTH: 0px; MARGIN: 0px; PADDING-LEFT: 0px; BORDER-SPACING: 0; PADDING-RIGHT: 0px; BORDER-COLLAPSE: collapse; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; PADDING-TOP: 0px"
width="100%" bgColor=#f1f0f9 align=left>
<TBODY>
<TR>
<TD
style="PADDING-BOTTOM: 0px; LINE-HEIGHT: 15px; PADDING-LEFT: 12px; PADDING-RIGHT: 12px; FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #6a4b92; FONT-SIZE: 12px; PADDING-TOP: 12px"
vAlign=top align=left><B>Products are for research use only
and are not intended for human use. We do not sell to
patients.</B> </TD></TR>
<TR>
<TD
style="PADDING-BOTTOM: 12px; LINE-HEIGHT: 15px; PADDING-LEFT: 12px; PADDING-RIGHT: 12px; FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #2b2b2b; FONT-SIZE: 12px; PADDING-TOP: 7px"
vAlign=top align=left>If you no longer wish to receive these
emails you may <A
style="FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #ff6600; FONT-SIZE: 12px"
href="http://medchemexpress.benchurl.com/c/l?u=A2354DF&e=101B0B6&c=98B9B&t=0&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&seq=1"
target=_blank>unsubscribe</A> at any time.
</TD></TR></TBODY></TABLE></TD></TR>
<TR>
<TD
style="PADDING-BOTTOM: 0px; PADDING-LEFT: 17px; PADDING-RIGHT: 13px; PADDING-TOP: 0px"
vAlign=top align=right>
<TABLE
style="PADDING-BOTTOM: 0px; BORDER-RIGHT-WIDTH: 0px; MARGIN: 0px; PADDING-LEFT: 0px; BORDER-SPACING: 0; PADDING-RIGHT: 0px; BORDER-COLLAPSE: collapse; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; PADDING-TOP: 0px"
width="100%"><!-- Subtitle 1 -->
<TBODY>
<TR>
<TD
style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 30px"
height=38 vAlign=top>
<P
style="MARGIN: 0px; FONT: 14px/36px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"
align=left><B><SPAN
style="COLOR: #6062a9; FONT-SIZE: 20px">SARS-CoV-2</SPAN></B>
<SPAN style="MARGIN: 0px 2px 0px 0px">—</SPAN> <SPAN>The
Battle against Coronavirus has just Begun</SPAN> </P></TD></TR>
<TR>
<TD
style="TEXT-ALIGN: justify; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 14px/20px Arial, Helvetica, sans-serif; COLOR: #2b2b2b; PADDING-TOP: 3px"
vAlign=top align=left><SPAN style="MARGIN-RIGHT: 8px">•</SPAN>
SARS-CoV-2 showed highly pathogenic, caused severe or even
life-threatening diseases, and still transmitted from
person-to-person. </TD></TR>
<TR>
<TD
style="TEXT-ALIGN: justify; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 14px/20px Arial, Helvetica, sans-serif; COLOR: #2b2b2b; PADDING-TOP: 8px"
vAlign=top align=left><SPAN
style="MARGIN-RIGHT: 10px">•</SPAN> The World Health
Organization declared a global pandemic as the coronavirus
(SARS-CoV-2) rapidly spreads across the world. </TD></TR>
<TR>
<TD
style="TEXT-ALIGN: justify; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 14px/20px Arial, Helvetica, sans-serif; COLOR: #2b2b2b; PADDING-TOP: 8px"
vAlign=top align=left><SPAN
style="MARGIN-RIGHT: 10px">•</SPAN> Until now, no drugs or
biologics have been proven to be effective for the prevention
or treatment of COVID-19. </TD></TR><!-- Subtitle 2-->
<TR>
<TD
style="PADDING-BOTTOM: 3px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 24px"
height=38 vAlign=top>
<P
style="MARGIN: 0px; FONT: 14px/36px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"
align=left><B
style="COLOR: #6062a9; FONT-SIZE: 20px"><SPAN>SARS-CoV-2</SPAN></B>
<SPAN style="MARGIN: 0px 2px 0px 0px">—</SPAN> <SPAN>Promising
Antiviral Agents</SPAN> </P></TD></TR>
<TR>
<TD
style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top>
<TABLE
style="PADDING-BOTTOM: 0px; BORDER-RIGHT-WIDTH: 0px; MARGIN: 0px; PADDING-LEFT: 0px; BORDER-SPACING: 0; PADDING-RIGHT: 0px; BORDER-COLLAPSE: collapse; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; PADDING-TOP: 0px"
width="100%"><!-- row-1 -->
<TBODY>
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=50 vAlign=top width=135>
<P
style="MARGIN: 7px 16px 3px auto; FONT: 14px/20px Arial, Helvetica, sans-serif; COLOR: #ffffff"
align=right><B><A
style="COLOR: #fff; TEXT-DECORATION: none"
href="http://medchemexpress.benchurl.com/c/l?u=A2354E0&e=101B0B6&c=98B9B&t=0&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&seq=1"
target=_blank><SPAN>Favipiravir <BR>(T-705)</SPAN></A>
</B></P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #fff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top width=532>
<P
style="MARGIN: 7px 11px 3px 12px; FONT: 14px/20px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"><SPAN>Selectively
and potently inhibits the RNA-dependent RNA
polymerase(RdRp) of RNA viruses. Shows good clinical
efficacy in treating COVID-19.</SPAN> </P></TD></TR><!-- row-2 -->
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=50 vAlign=top>
<P
style="MARGIN: 7px 16px 3px auto; FONT: 14px/20px Arial, Helvetica, sans-serif; COLOR: #ffffff"
align=right><B><A
style="COLOR: #fff; TEXT-DECORATION: none"
href="http://medchemexpress.benchurl.com/c/l?u=A2354E1&e=101B0B6&c=98B9B&t=0&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&seq=1"
target=_blank><SPAN>Remdesivir <BR>(GS-5734)</SPAN></A>
</B></P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #fff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top>
<P
style="MARGIN: 7px 11px 3px 12px; FONT: 14px/20px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"><SPAN>A
nucleotide analog inhibitor of RdRp. Against SARS-CoV,
MERS-CoV and Ebola virus. Effectively inhibits
SARS-CoV-2 in vitro. Enters phase III trial.</SPAN>
</P></TD></TR><!-- row-3 -->
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=50 vAlign=center>
<P
style="MARGIN: 7px 16px 3px auto; FONT: 14px/20px Arial, Helvetica, sans-serif; COLOR: #ffffff"
align=right><B><A
style="COLOR: #fff; TEXT-DECORATION: none"
href="http://medchemexpress.benchurl.com/c/l?u=A2354E2&e=101B0B6&c=98B9B&t=0&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&seq=1"
target=_blank><SPAN>Chloroquine <BR>Phosphate</SPAN></A>
</B></P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #fff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top>
<P
style="MARGIN: 7px 11px 3px 12px; FONT: 14px/20px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"><SPAN>An
antimalarial agent. Inhibits autophagy and toll-like
receptors (TLRs). Effectively inhibits SARS-CoV-2 in
vitro. FDA approved.</SPAN> </P></TD></TR><!-- row-4 -->
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=50 vAlign=top>
<P
style="MARGIN: 7px 16px 3px auto; FONT: 14px/20px Arial, Helvetica, sans-serif; COLOR: #ffffff"
align=right><B><A
style="COLOR: #fff; TEXT-DECORATION: none"
href="http://medchemexpress.benchurl.com/c/l?u=A2354E3&e=101B0B6&c=98B9B&t=0&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&seq=1"
target=_blank><SPAN>Hydroxychloro- <BR>quine
sulfate</SPAN> </A></B></P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #fff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top>
<P
style="MARGIN: 7px 11px 3px 12px; FONT: 14px/20px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"><SPAN>An
antimalarial and anti-inflammatory agent. Inhibits
TLR7/9 signaling. Efficiently inhibits SARS-CoV-2
infection in vitro. FDA approved.</SPAN>
</P></TD></TR></TBODY></TABLE></TD></TR><!-- Subtitle 3-->
<TR>
<TD
style="TEXT-ALIGN: justify; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 16px/27px Arial, Helvetica, sans-serif; COLOR: #2b2b2b; PADDING-TOP: 28px"
vAlign=top align=left>MedChemExpress <A
style="COLOR: #6062a9; TEXT-DECORATION: none"
href="http://medchemexpress.benchurl.com/c/l?u=A2354E4&e=101B0B6&c=98B9B&t=0&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&seq=1"
target=_blank><SPAN>Anti-COVID-19 Compound Library</SPAN></A>
based on Relevant Proteins: </TD></TR>
<TR>
<TD
style="TEXT-ALIGN: justify; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 14px/21px Arial, Helvetica, sans-serif; COLOR: #2b2b2b; PADDING-TOP: 3px"
vAlign=top align=left>We conduct <B>Virtual Screening</B> of
approved compound library and clinical compound library based
on 3CLpro (PDB ID: 6LU7), RdRp, Spike Glycoprotein (PDB ID:
6VSB), nsp15 (PDB ID: 6VWW), PLpro and ACE2 Structure. </TD></TR>
<TR>
<TD
style="TEXT-ALIGN: justify; PADDING-BOTTOM: 7px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 14px/21px Arial, Helvetica, sans-serif; COLOR: #2b2b2b; PADDING-TOP: 18px"
vAlign=top align=left>Partial Screening Library Data: </TD></TR>
<TR>
<TD
style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top>
<TABLE
style="PADDING-BOTTOM: 0px; BORDER-RIGHT-WIDTH: 0px; MARGIN: 0px; PADDING-LEFT: 0px; BORDER-SPACING: 0; PADDING-RIGHT: 0px; BORDER-COLLAPSE: collapse; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; PADDING-TOP: 0px"
width="100%"><!-- row-1 -->
<TBODY>
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=30 width=135>
<P style="LINE-HEIGHT: 21px; MARGIN: 6px 0px 3px"
align=center><B><SPAN
style="FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #ffffff; FONT-SIZE: 14px">SARS-CoV-2</SPAN></B>
</P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=30 width=125>
<P style="LINE-HEIGHT: 21px; MARGIN: 6px 0px 3px"
align=center><B><SPAN
style="FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #ffffff; FONT-SIZE: 14px">Compounds</SPAN></B>
</P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=30 width=404>
<P style="LINE-HEIGHT: 21px; MARGIN: 6px 0px 3px 14px"
align=left><B><SPAN
style="FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #ffffff; FONT-SIZE: 14px">Information</SPAN></B>
</P></TD></TR><!-- row-2 -->
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=101 vAlign=center rowSpan=3 width=135>
<P
style="MARGIN: 0px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #fff"
align=center><B><SPAN>3CLpro</SPAN></B> </P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=28 vAlign=top width=125>
<P
style="MARGIN: 7px 11px 3px 12px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"
align=center><SPAN>Saquinavir</SPAN> </P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=28 vAlign=top width=404>
<P
style="MARGIN: 7px 11px 3px 14px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"><SPAN>An
HIV Protease inhibitor. FDA approved.</SPAN> </P></TD></TR><!-- row-3 -->
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=23 vAlign=top width=125>
<P
style="MARGIN: 3px 11px 2px 12px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"
align=center><SPAN>Carfilzomib</SPAN> </P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=23 vAlign=top width=404>
<P
style="MARGIN: 3px 11px 2px 14px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"><SPAN>An
irreversible proteasome inhibitor. FDA approved.</SPAN>
</P></TD></TR><!-- row-4 -->
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=46 vAlign=top width=125>
<P
style="MARGIN: 5px 11px 0px 12px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"
align=center><SPAN>Nelfinavir</SPAN> </P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=46 vAlign=top width=404>
<P
style="MARGIN: 5px 11px 5px 14px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"><SPAN>An
orally bioavailable HIV-1 protease inhibitor (Ki=2 nM)
and antiviral agent. FDA approved.</SPAN> </P></TD></TR><!-- row-5 -->
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; TEXT-ALIGN: center; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=45 vAlign=center width=135>
<P
style="MARGIN: 0px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #fff"
align=center><B><SPAN>S Protein & ACE2</SPAN></B>
</P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top width=125>
<P
style="MARGIN: 5px 11px auto 12px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"
align=center><SPAN>Bimosiamose</SPAN> </P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top width=404>
<P
style="MARGIN: 5px 11px 4px 14px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"><SPAN>A
nonoligosaccharide pan-selectin inhibitor and has anti-
<BR>inflammatory effects. Phase 2.</SPAN> </P></TD></TR><!-- row-6 -->
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=34 vAlign=center width=135>
<P
style="MARGIN: 0px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #fff"
align=center><B><SPAN>RdRp</SPAN></B> </P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top width=125>
<P
style="MARGIN: 8px 11px auto 12px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"
align=center><SPAN>Zanamivir</SPAN> </P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top width=404>
<P
style="MARGIN: 8px 11px 8px 14px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"><SPAN>An
influenza viral neuraminidase inhibitor. FDA
approved.</SPAN> </P></TD></TR><!-- row-7 -->
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=46 vAlign=center width=135>
<P
style="MARGIN: 0px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #fff"
align=center><B><SPAN>nsp15</SPAN></B> </P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top width=125>
<P
style="MARGIN: 5px 11px auto 12px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"
align=center><SPAN>Ribavirin</SPAN> </P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top width=404>
<P
style="MARGIN: 7px 11px 3px 14px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"><SPAN>An
antiviral agent against a broad spectrum of viruses
including HCV, HIV, and RSV. FDA approved.</SPAN>
</P></TD></TR><!-- row-8 -->
<TR>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #6062a9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
height=46 vAlign=center width=135>
<P
style="MARGIN: 0px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #fff"
align=center><B><SPAN>PLpro</SPAN></B> </P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top width=125>
<P
style="MARGIN: 5px 11px 5px 12px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"
align=center><SPAN>Epetraborole <BR>hydrochloride</SPAN>
</P></TD>
<TD
style="BORDER-BOTTOM: #ffffff 2px solid; BORDER-LEFT: #ffffff 3px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #f1f0f9; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"
vAlign=top width=404>
<P
style="MARGIN: 5px 11px 5px 14px; FONT: 14px/18px Arial, Helvetica, sans-serif; COLOR: #2b2b2b"><SPAN>A
leucyl-tRNA synthetase (LeuRS) inhibitor. Intended for
the infections caused by Gram-negative bacteria. Phase
2.</SPAN> </P></TD></TR></TBODY></TABLE></TD></TR><!-- Contact US -->
<TR>
<TD
style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 28px"
vAlign=top colSpan=2>
<TABLE
style="PADDING-BOTTOM: 0px; BORDER-RIGHT-WIDTH: 0px; MARGIN: 0px; PADDING-LEFT: 0px; BORDER-SPACING: 0; PADDING-RIGHT: 0px; BORDER-COLLAPSE: collapse; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; PADDING-TOP: 0px"
width="100%" align=left>
<TBODY>
<TR>
<TD
style="FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #333; FONT-SIZE: 12px"
height=18 vAlign=top rowSpan=2 width=106
align=left><B>MCE USA</B></TD>
<TD
style="FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #333; FONT-SIZE: 12px"
height=18 vAlign=top width=145 align=left>Tel:
609-228-6898 </TD><!--<td width="145" height="18" align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#333">Fax: 609-228-5909</td>-->
<TD
style="FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #333; FONT-SIZE: 12px"
height=18 vAlign=top width=419 align=left>E-mail: <A
style="COLOR: #333; TEXT-DECORATION: none">sales@MedChemExpress.com</A>
</TD></TR>
<TR>
<TD
style="PADDING-BOTTOM: 5px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #333; FONT-SIZE: 12px; PADDING-TOP: 0px"
height=18 vAlign=top colSpan=2 align=left>Address: 1
Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
</TD></TR>
<TR>
<TD
style="FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #333; FONT-SIZE: 12px"
height=18 vAlign=top rowSpan=2 align=left><B>MCE
Europe</B></TD>
<TD
style="FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #333; FONT-SIZE: 12px"
height=18 vAlign=top align=left>Tel: +4686500910 </TD>
<TD
style="FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #333; FONT-SIZE: 12px"
height=18 vAlign=top align=left>E-mail: <A
style="COLOR: #333; TEXT-DECORATION: none">eu.sales@MedChemExpress.com</A>
</TD></TR>
<TR>
<TD
style="PADDING-BOTTOM: 13px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #333; FONT-SIZE: 12px; PADDING-TOP: 0px"
height=18 vAlign=top colSpan=2 align=left>Address:
Bergkällavägen 37C 192 79 Sollentuna SWEDEN
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></TD></TR><!-- Footer -->
<TR>
<TD
style="PADDING-BOTTOM: 20px; PADDING-LEFT: 19px; PADDING-RIGHT: 11px; PADDING-TOP: 10px"
bgColor=#f6f4f5 vAlign=top>
<TABLE
style="PADDING-BOTTOM: 0px; BORDER-RIGHT-WIDTH: 0px; MARGIN: 0px; PADDING-LEFT: 0px; BORDER-SPACING: 0; PADDING-RIGHT: 0px; BORDER-COLLAPSE: collapse; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; PADDING-TOP: 0px"
width="100%" align=left>
<TBODY>
<TR>
<TD
style="PADDING-BOTTOM: 0px; LINE-HEIGHT: 15px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #6a4b92; FONT-SIZE: 12px; PADDING-TOP: 7px"
vAlign=top align=left><B>We respect your privacy and do not
share or sell your information to third parties.</B>
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE><IMG
style="DISPLAY: none" border=0 alt=""
src="http://medchemexpress.benchurl.com/c/o?e=101B0B6&c=98B9B&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&relid=A0B1B17"
width=1 height=1> <!-- Online Path -->
<DIV class=bmeheader align=center>
<DIV style="FONT-FAMILY: Arial, Verdana; FONT-SIZE: 12px" class=bmeheader
align=center>
<TABLE
style="PADDING-BOTTOM: 20px; PADDING-LEFT: 20px; PADDING-RIGHT: 20px; PADDING-TOP: 20px"
class=container-table border=0 cellSpacing=0 cellPadding=0 width=600>
<TBODY>
<TR>
<TD class=preheader-table vAlign=top align=middle>
<DIV
style="PADDING-BOTTOM: 5px; LINE-HEIGHT: 140%; FONT-FAMILY: Arial, Helvetica, sans-serif; COLOR: #666666; FONT-SIZE: 11px"
align=center><A style="COLOR: #16a7e0"
href="http://medchemexpress.benchurl.com/c/v?e=101B0B6&c=98B9B&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&relid=A0B1B17"
target=_new>View this email in your browser</A> <BR>You are receiving this
email because of your relationship with medchemexpress. Please <A
style="COLOR: #16a7e0"
href="http://medchemexpress.benchurl.com/c/opt?e=101B0B6&c=98B9B&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&relid=A0B1B17"
target=_new>reconfirm</A> your interest in receiving emails from us.
</DIV></TD></TR></TBODY></TABLE></DIV></DIV><!-- /Online Path -->
<TABLE style="COLOR: #666666" class=blk border=0 cellSpacing=0 cellPadding=0
width="100%" name="blk_footer">
<TBODY>
<TR>
<TD
style="PADDING-BOTTOM: 20px; PADDING-LEFT: 20px; PADDING-RIGHT: 20px; PADDING-TOP: 20px"
vAlign=top align=left name="tblCell">
<TABLE border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR>
<TD style="TEXT-ALIGN: center" align=middle
name="bmeBadgeText"><SPAN
style="LINE-HEIGHT: 140%; FONT-FAMILY: Arial, Helvetica, sans-serif; FONT-SIZE: 11px; FONT-WEIGHT: normal"
id=spnFooterText>Address: 9 Deer Park Drive, Suite K2,, Monmouth
Junction, New Jersey, 08852</SPAN> <BR><BR><SPAN
style="LINE-HEIGHT: 140%; FONT-FAMILY: Arial, Helvetica, sans-serif; FONT-SIZE: 11px; FONT-WEIGHT: normal"><A
href="http://medchemexpress.benchurl.com/c/su?e=101B0B6&c=98B9B&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&relid=A0B1B17"></A>|
<A style="TEXT-DECORATION: underline" class=bmefootertext
href="http://medchemexpress.benchurl.com/c/s?e=101B0B6&c=98B9B&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&relid=A0B1B17">Manage
Subscription</A> | <A style="TEXT-DECORATION: underline"
class=bmefootertext
href="http://medchemexpress.benchurl.com/c/f?e=101B0B6&c=98B9B&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&relid=A0B1B17">Forward
Email</A> | <A style="TEXT-DECORATION: underline"
class=bmefootertext
href="http://medchemexpress.benchurl.com/Abuse?e=101B0B6&c=98B9B&l=&email=2g9tljG95M33vn6Zn85VNQ%3D%3D&relid=A0B1B17">Report
Abuse</A> <BR></SPAN></TD></TR></TBODY></TABLE>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV style="FONT: 10pt arial">
<DIV style="BACKGROUND: #e4e4e4; font-color: black"><B>From:</B> <A
title=newsletter@emailchemscene.com
href="mailto:newsletter@emailchemscene.com">MedChemExpress LLC</A> </DIV>
<DIV><B>Sent:</B> Wednesday, March 25, 2020 6:30 PM</DIV>
<DIV><B>Subject:</B> SARS-CoV-2: The Battle against COVID-19 has just
Begun</DIV>
<DIV> </DIV></DIV></TD></TR></TBODY></TABLE></BODY></HTML>